Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346860 | 0.86 | SLC6A4 (0.56) | SLC6A4MAOAGSK3BRAB9ANPC1 | |
| SCHEMBL7496543 | 0.80 | CA12 (0.52) | SLC6A4MAOARAB9ANPC1SLC2A1 | |
| SCHEMBL10316183 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOAGSK3BRAB9ANPC1 | |
| SCHEMBL8591154 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOAGSK3BRAB9ANPC1 | |
| SCHEMBL9793575 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOAGSK3BRAB9ANPC1 | |
| SCHEMBL10843454 | 0.77 | MAOA (0.53) | MAOARAB9ANPC1SLC2A1CA12 | |
| SCHEMBL169195 | 0.76 | SLC6A4 (0.48) | SLC6A4MAOARAB9ANPC1ALDH1A1 | |
| SCHEMBL13940796 | 0.76 | SLC6A4 (0.48) | SLC6A4MAOAALDH1A1 | |
| SCHEMBL19454683 | 0.74 | SLC6A4 (0.52) | SLC6A4MAOAGSK3BRAB9ANPC1 | |
| SCHEMBL3371540 | 0.74 | NR1H2 (0.50) | SLC6A4MAOARAB9ANPC1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-6030978-A | EXHIBIT FUNGICIDAL EFFECT OR GROWTH-INHIBITORY EFFECT AGAINST FUNGI INCLUDING CUTANEOUS FILAMENTOUS FUNGUS, SUCH AS EPIDERMOPHYTON, MICROSPORUM, TRICHOPHYTON, SPOROTHRIX SCHENCKII, ASPERGILLUS OR CANDIDA; NONTOXICITY; | HANWHA CORPORATION (KR) | 2000-02-29 | — | — | US | claimed |
| US-6008356-A | BRBERINE SALT DERIVATIVE IS REACTED WITH SODIUM TETRABORATE AND POTASSIUM CARBONATE IN ALCOHOL SOLVEANT TO FORM INTERMEDIATE, REACTING INTERMEDIATE WITH ALKYL SUBSTITUENT IN ACETONITRILE SOLVENT, OXIDIZING THE FORMED INTERMEDIATE | HANWHA CORPORATION (KR) | 1999-12-28 | — | — | US | claimed |
| US-4591376-A | PLANT GROWTH REGULATORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-05-27 | — | — | US | claimed |
| EP-0126234-A2 | 1,2,3-Thiadiazol-3-in-5-ylidene ureas, their preparation and compositions as plant-growth regulators and defoliants | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-11-28 | — | — | EP | claimed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2022-01-27 | — | — | US | disclosed |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-10-05 | — | — | US | disclosed |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-07-22 | — | — | US | disclosed |
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-05-11 | — | — | US | disclosed |
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2020-09-24 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5563159-A | Dithiocarbonimide derivatives useful as acaricidal, fungicidal, and insecticidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| EP-0649839-A1 | Isoquinolinone-, phthalazinone-, quinazolinone- and benzotriazolinone derivatives, their preparation and their use as anti-thrombotics | LUITPOLD PHARMA GmbH (DE) | 1995-04-26 | — | — | EP | disclosed |
| WO-1995009842-A1 | ISOQUINOLINONE-, PHTHALAZINONE-, QUINAZOLINONE- AND BENZOTRIAZOLINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTI-THROMBOTICS | LUITPOLD PHARMA GMBH (DE) | 1995-04-13 | — | — | WO | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| US-4591376-A | PLANT GROWTH REGULATORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-05-27 | — | — | US | disclosed |
| EP-0126234-A2 | 1,2,3-Thiadiazol-3-in-5-ylidene ureas, their preparation and compositions as plant-growth regulators and defoliants | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | SLC6A4 89/4885MAOA 296/4885GSK3B 2923/4885 |
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | SLC6A4 606/4885MAOA 837/4885GSK3B 3057/4885 |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | SLC6A4 606/4885MAOA 837/4885GSK3B 3057/4885 |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | SLC6A4 606/4885MAOA 837/4885GSK3B 3057/4885 |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | SLC6A4 89/4885MAOA 296/4885GSK3B 2923/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | SLC6A4 89/4885MAOA 296/4885GSK3B 2923/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | SLC6A4 89/4885MAOA 296/4885GSK3B 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.